17900-68-4

Basic information

• Product Name: 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one
• Synonyms: 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one;1-Phenyl-3,4-dimethyl-5(4H)-pyrazolone;Einecs 241-844-1;3,4-DiMethyl-1-phenyl-1H-pyrazol-5(4H)-one
• CAS NO: 17900-68-4
• Molecular Formula: C₁₁H₁₂N₂O
• Molecular Weight: 188.22578
• EINECS: 241-844-1
• Mol File: 17900-68-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 334.5 °C at 760 mmHg
• Flash Point: 156.1 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 0.00247mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one(17900-68-4)
• EPA Substance Registry System: 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one(17900-68-4)

Safety Data

• Hazardous Substances Data: 17900-68-4(Hazardous Substances Data)

Usage

General Description

2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one is a chemical compound with the molecular formula C11H14N2O. It is a pyrazolone derivative with a phenyl group and two methyl groups attached to the pyrazole ring. 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has been studied for its potential biological activities, including anti-inflammatory and analgesic properties. Additionally, it has been investigated for its potential application as a corrosion inhibitor in metal surfaces. Overall, 2,4-dihydro-4,5-dimethyl-2-phenyl-3H-pyrazol-3-one has versatile uses and potential benefits in various fields of chemistry and biology.

InChI:InChI=1/C11H12N2O/c1-8-9(2)12-13(11(8)14)10-6-4-3-5-7-10/h3-7,12H,1-2H3

Upstream product

• 1694-31-1 tert-butyl acetoacetate 
• 100-63-0 phenylhydrazine 
• 74-88-4 methyl iodide 
• 1431522-60-9 4-(N-hydroxylamine)-4-methyl-N-phenyl-5-methylpyrazolone 
• 609-14-3 2-acetylpropanoic acid ethyl ester 
• 85920-63-4 5-(1-hydroxyethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 1510821-64-3 4,5-dimethyl-2-(2-morpholinophenyl)-1H-pyrazol-3(2H)-one 

Relevant articles and documents

Rhodium-Catalyzed [4+2] Annulation of N-Aryl Pyrazolones with Diazo Compounds To Access Pyrazolone-Fused Cinnolines

An efficient synthesis of novel dinitrogen-fused heterocycles such as pyrazolo[1,2-a]cinnoline derivatives have been accomplished by the rhodium(III)-catalyzed reaction of N-arylpyrazol-5-ones with α-diazo compounds. This reaction proceeds through a cascade C?H activation/intramolecular cyclization with a broad substrate scope. Furthermore, this protocol is successfully extended to the unusual phosphorus-containing α-diazo compounds and cyclic diazo compounds as the cross-coupling partners to deliver the two new kinds of pyrazolo[1,2-a]cinnolinones. The control experiments were performed to reveal insight into the mechanism of this reaction, involving reversible C?H activation, migratory insertion of the diazo compound, and cascade cyclization as the key steps of the transformation. Moreover, gram-scale synthesis and further transformation of the target product demonstrate the synthetic utility of the present protocol.

Catch-and-release of HNO with pyrazolones

A new and versatile class of HNO donors, the (hydroxylamino)pyrazolone (HAPY) series of HNO donors utilizing pyrazolone (PY) leaving groups, is described. HNO, the smallest N-based aldehyde equivalent, is used as a reagent along with a variety of PY compounds to synthesize the desired HAPY donors in what can be considered an N-selective HNO-aldol reaction in up to quantitative yields. The bimolecular rate constant of HNO with PY in pH 7.4 phosphate buffer at 37 °C can reach 8 × 105 M-1 s-1. In 1H NMR experiments, the HAPY compounds generate HNO quantitatively (trapped as a phosphine aza-ylide) with half-lives spanning 3 orders of magnitude (minutes to days) under physiologically relevant conditions. B3LYP/6-31G calculations confirm the energetically favorable reactions between HNO and the PY enol and enolate, whereas HNO release is expected to occur through the oxyanion (OHN-PY) of each HAPY compound. HNO has been shown to provide functional support to failing hearts.

DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE

It is intended to provide drugs for treating and/or preventing ischemic diseases which are safe and have little side effects. Namely, drugs comprising a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.